Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 2
2018 2
2019 3
2020 8
2021 9
2022 6
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I, Rumbo-Feal S, Galán-Sánchez F, Beceiro A, Arca-Suárez J, Oliver A, Bou G. Lasarte-Monterrubio C, et al. J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi: 10.1093/jac/dkac241. J Antimicrob Chemother. 2022. PMID: 35904000
Bacterial Pathogenesis and Antimicrobial Strategy.
Vázquez-Ucha JC, Martínez-Guitián M. Vázquez-Ucha JC, et al. Antibiotics (Basel). 2023 Dec 18;12(12):1750. doi: 10.3390/antibiotics12121750. Antibiotics (Basel). 2023. PMID: 38136784 Free PMC article.
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, Aja-Macaya P, Guijarro-Sánchez P, Rumbo-Feal S, Muíño-Andrade M, Fernández-González A, Martínez-Guitián M, Beceiro A, Rodríguez-Iglesias M, Oliver A, Arca-Suárez J, Galán-Sánchez F, Bou G. Alonso-García I, et al. J Antimicrob Chemother. 2023 May 3;78(5):1195-1200. doi: 10.1093/jac/dkad062. J Antimicrob Chemother. 2023. PMID: 36918743
Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC, Alonso-Garcia I, Guijarro-Sánchez P, Lasarte-Monterrubio C, Álvarez-Fraga L, Cendón-Esteve A, Outeda M, Maceiras R, Peña-Escolano A, Martínez-Guitián M, Arca-Suárez J, Bou G, Beceiro A; GEMARA-SEIMC/REIPI Enterobacterales Study Group. Vázquez-Ucha JC, et al. Int J Antimicrob Agents. 2023 Apr;61(4):106738. doi: 10.1016/j.ijantimicag.2023.106738. Epub 2023 Feb 3. Int J Antimicrob Agents. 2023. PMID: 36736925
Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1.
Lasarte-Monterrubio C, Guijarro-Sánchez P, Vázquez-Ucha JC, Alonso-Garcia I, Alvarez-Fraga L, Outeda M, Martinez-Guitian M, Peña-Escolano A, Maceiras R, Lence E, González-Bello C, Arca-Suárez J, Bou G, Beceiro A. Lasarte-Monterrubio C, et al. Antimicrob Agents Chemother. 2023 May 17;67(5):e0150522. doi: 10.1128/aac.01505-22. Epub 2023 Apr 13. Antimicrob Agents Chemother. 2023. PMID: 37195077 Free PMC article.
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales.
Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño M, Álvarez-Fraga L, Alonso-García I, Arca-Suárez J, Bou G, Beceiro A; GEMARA-SEIMC/REIPI Enterobacterales Study Group. Vázquez-Ucha JC, et al. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0167621. doi: 10.1128/AAC.01676-21. Epub 2021 Nov 22. Antimicrob Agents Chemother. 2022. PMID: 34807754 Free PMC article.
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification.
Gato E, Guijarro-Sánchez P, Alonso-García I, Pedraza-Merino R, Conde A, Lence E, Rumbo-Feal S, Peña-Escolano A, Lasarte-Monterrubio C, Blanco-Martín T, Fernández-González A, Fernández-López MDC, Maceiras R, Martínez-Guitián M, Vázquez-Ucha JC, Martínez-Martínez L, González-Bello C, Arca-Suárez J, Beceiro A, Bou G. Gato E, et al. Int J Antimicrob Agents. 2023 Oct;62(4):106935. doi: 10.1016/j.ijantimicag.2023.106935. Epub 2023 Aug 3. Int J Antimicrob Agents. 2023. PMID: 37541530
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T, Alonso-García I, González-Pinto L, Outeda-García M, Guijarro-Sánchez P, López-Hernández I, Pérez-Vázquez M, Aracil B, López-Cerero L, Fraile-Ribot P, Oliver A, Vázquez-Ucha JC, Beceiro A, Bou G, Arca-Suárez J; GEMARA/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT). Blanco-Martín T, et al. Int J Antimicrob Agents. 2024 Mar 19;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Online ahead of print. Int J Antimicrob Agents. 2024. PMID: 38513748 Free article.
Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales".
Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño M, Álvarez-Fraga L, Alonso-García I, Arca-Suárez J, Bou G, Beceiro A. Vázquez-Ucha JC, et al. Antimicrob Agents Chemother. 2022 May 17;66(5):e0035322. doi: 10.1128/aac.00353-22. Epub 2022 Apr 26. Antimicrob Agents Chemother. 2022. PMID: 35471039 Free PMC article. No abstract available.
39 results